Artificial cells microencapsulated genetically engineered E. coli DH5 cells for the lowering of plasma creatinine in-vitro and in-vivo.
High level of plasma creatinine occurs in renal insufficiency, uremia, and other diseases. At present lowering of this metabolite is done by using dialysis and other techniques. In this article, we report the use of artificial cells microencapsulated genetically engineered E. coli DH5 cells for lowering plasma creatinine in-vitro and in-vivo. Result shows that artificial cells were able to lower plasma creatinine in-vitro from 21.80 +/- 1.10 mg/dl to 21.80 +/- 1.10 mg/dl in 60 minutes and to 19.34 +/- 0.60 mg/dl in 3 hours. Result also shows that when given orally on a daily basis, artificial cells microencapsulated genetically engineered E. coli DH5 cells were also able to lower plasma creatinine in rats.
Prakash
S
S
Artificial Cells and Organs Research Centre, Faculty of Medicine, McGill University, Quebec, Canada.
Chang
T M
TM
D000818:Animals; D003404:Creatinine / Q000097:blood*; D004195:Disease Models, Animal; D004339:Drug Compounding / Q000379:methods*; D004926:Escherichia coli / Q000235:genetics* / Q000378:metabolism; D005818:Genetic Engineering; D008297:Male; D008567:Membranes, Artificial; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D014511:Uremia / Q000628:therapy
D008567:Membranes, Artificial; D003404:Creatinine